Clearmind Medicine reports ongoing Phase I/IIa CMND-100 trial treatment at U.S. sites for alcohol use disorder

Reuters03-19
<a href="https://laohu8.com/S/CMND">Clearmind Medicine</a> reports ongoing Phase I/IIa CMND-100 trial treatment at U.S. sites for alcohol use disorder
  • Clearmind reported continued treatment of participants in the third cohort of its FDA-approved Phase I/IIa clinical trial of CMND-100, an oral MEAI-based drug candidate being studied for Alcohol Use Disorder.
  • The multinational, multicenter study is evaluating safety, tolerability, pharmacokinetics, and preliminary efficacy in patients with moderate to severe Alcohol Use Disorder.
  • Ongoing treatment at Yale University and Johns Hopkins University has proceeded with no serious adverse events reported to date.
  • Clearmind did not specify that new results have been presented or provide a timeline for future presentation of results.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Clearmind Medicine Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603190845PRIMZONEFULLFEED9675263) on March 19, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment